SQZ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Jul 2023 @ 13:00):

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions...

Stats
Today's Volume	30.14M
Average Volume	553 611
Market Cap	12.83M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.201
ATR14	$0.0350 (68.86%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-14	Vink Patrick V.j.j.	Buy	39 875	Stock Option
2023-06-14	Srivastava Sapna	Buy	39 875	Stock Option
2023-06-14	Schulman Amy W	Buy	39 875	Stock Option
2023-06-14	Schegerin Marc	Buy	39 875	Common Stock
2023-06-14	Jensen Klavs F.	Buy	39 875	Stock Option

INSIDER POWER
99.95
Last 97 transactions
Buy: 14 673 100 \| Sell: 2 196 730

Volume Correlation

Long: 0.00 (neutral)

Short: -0.22 (neutral)

Signal:(30.626) Neutral

SQZ Biotechnologies Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SQZ Biotechnologies Correlation - Currency/Commodity

-0.64
( weak negative )

-0.61
( weak negative )

0.00
( neutral )

0.74
( moderate )

-0.64
( weak negative )

0.35
( neutral )

SQZ Biotechnologies Financials

Annual	2022
Revenue:	$21.03M
Gross Profit:	$21.03M (100.00 %)
EPS:	$-2.72

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

Q2	2023
Revenue:	$178 000
Gross Profit:	$178 000 (100.00 %)
EPS:	$-0.570

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.580

Financial Reports:

No articles found.

SQZ Biotechnologies

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.